There is a strong quote from RP, I will have to locate it. But RP has used before the term necessary and sufficient when describing the ccr5/metastasis connection.
On a side note (while searching for that quote, still looking), but I found another new paper published last month. We need to get this cancer trial started! So much excitement in the research community about ccr5/cancer and very very few researchers and potential investors know of leronlimab and the significance of what we possibly have here.
http://www.haematologica.org/content/104/3/564
CCR5 Antagonism By Maraviroc Inhibits Hodgkin Lymphoma Microenvironment Interactions And Xenograft Growth
Abstract
On a side note (while searching for that quote, still looking), but I found another new paper published last month. We need to get this cancer trial started! So much excitement in the research community about ccr5/cancer and very very few researchers and potential investors know of leronlimab and the significance of what we possibly have here.
http://www.haematologica.org/content/104/3/564
CCR5 Antagonism By Maraviroc Inhibits Hodgkin Lymphoma Microenvironment Interactions And Xenograft Growth
Abstract
Quote:Classic Hodgkin lymphoma tumor cells express a functional CCR5 receptor, and tumor tissues express high CCL5 levels, suggesting that CCL5-CCR5 signaling is involved in tumor-microenvironment formation and tumor growth. Using the CCR5 antagonist, maraviroc, and a neutralizing anti-CCL5 antibody, we found that CCL5 secreted by classic Hodgkin lymphoma cells recruited mesenchymal stromal cells and monocytes. The “education” of mesenchymal stromal cells by tumor cell-conditioned medium enhanced mesenchymal stromal cells’ proliferation and CCL5 secretion. In turn, educated mesenchymal stromal cell-conditioned medium increased the clonogenic growth of tumor cells and monocyte migration, but these effects were reduced by maraviroc. Monocyte education by tumor cell-conditioned medium induced their growth and reprogrammed them towards immunosuppressive tumor-associated macrophages that expressed IDO and PD-L1 and secreted IL-10, CCL17 and TGF-β. Educated monocyte-conditioned medium slowed the growth of phytohemagglutinin-activated lymphocytes. Maraviroc decreased tumor cell growth and synergized with doxorubicin and brentuximab vedotin. A three-dimensional heterospheroid assay showed that maraviroc counteracted both the formation and viability of heterospheroids generated by co-cultivation of tumor cells with mesenchymal stromal cells and monocytes. In mice bearing tumor cell xenografts, maraviroc reduced tumor growth by more than 50% and inhibited monocyte accumulation, without weight loss. Finally, in classic Hodgkin lymphoma human tumor tissues, CCL5 and CD68 expression correlated positively, and patients with high CCL5 levels had poor prognosis. In conclusion, since the present challenges are to find molecules counteracting the formation of the immunosuppressive tumor microenvironment or new, less toxic drug combinations, the repurposed drug maraviroc may represent a new opportunity for classic Hodgkin lym phoma treatment.
